Ganirelix

This classification denotes a gonadotropin releasing hormone inhibitor with the molecular formula C80H113ClN18O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IX503L9WN0, chemically known as d-alaninamide, n-acetyl-3-(1-naphthalenyl)-d-alanyl-4-chloro-d-phenylalanyl-3-(3-pyridinyl)-d-alanyl-l-seryl-l-tyrosyl-n6-(bis(ethylamino)methylene)-d-lysyl-l-leucyl-n6-(bis(ethylamino)methylene)-l-lysyl-l-prolyl- but generally known as ganirelix, which bears US NIH Compound Identifier 16130966. European Medicines Agency schedules Ganirelix in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07883MIG. The term GANIRELIX is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules ganirelix in its Anatomical Therapeutic Chemical (ATC) Classification. GANIRELIX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ganirelix under HS 29371900 and SITC 54154. As of Q4 2014, GANIRELIX remains the US FDA Preferred Term for this commodity. Ganirelix bears US NLM identifiers UMLS ID C0073629 and NCI Concept Code C77423. SMILES: CLC1CCC(CC(NC(=O)C(NC(=O)C)CC2CC3C(CC2)CCCC3)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2C(CCC2)C(=O)NC(C)C(=O)N)CCCC/N=C(/NCC)NCC)CC(C)C)CCCC/N=C(/NCC)NCC)CC2CCC(O)CC2)CO)CC2CCCNC2)CC1.